Rejection of InterMune’s Drug Told Early to FDA Advisers

Three members of an independent advisory panel say they received as much as a day’s notice in May 2010 before U.S. regulators rejected a drug from InterMune, now tied to an insider trading probe of SAC Capital Advisors.
Bloomberg